Evogene (EVGN) - Net Assets
Based on the latest financial reports, Evogene (EVGN) has net assets worth ILA17.25 Million ILA (≈ $46.25K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA26.09 Million ≈ $69.94K USD) and total liabilities (ILA8.83 Million ≈ $23.68K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Evogene's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA17.25 Million |
| % of Total Assets | 66.14% |
| Annual Growth Rate | -0.54% |
| 5-Year Change | -73.91% |
| 10-Year Change | -85.7% |
| Growth Volatility | 67.64 |
Evogene - Net Assets Trend (2006–2024)
This chart illustrates how Evogene's net assets have evolved over time, based on quarterly financial data. Also explore Evogene asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Evogene (2006–2024)
The table below shows the annual net assets of Evogene from 2006 to 2024. For live valuation and market cap data, see EVGN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA14.84 Million ≈ $39.78K |
-48.27% |
| 2023-12-31 | ILA28.68 Million ≈ $76.90K |
-17.55% |
| 2022-12-31 | ILA34.79 Million ≈ $93.27K |
-45.14% |
| 2021-12-31 | ILA63.42 Million ≈ $170.03K |
+11.49% |
| 2020-12-31 | ILA56.88 Million ≈ $152.50K |
-5.54% |
| 2019-12-31 | ILA60.22 Million ≈ $161.44K |
+19.70% |
| 2018-12-31 | ILA50.31 Million ≈ $134.87K |
-27.49% |
| 2017-12-31 | ILA69.38 Million ≈ $186.00K |
-20.52% |
| 2016-12-31 | ILA87.29 Million ≈ $234.02K |
-15.87% |
| 2015-12-31 | ILA103.75 Million ≈ $278.16K |
-10.62% |
| 2014-12-31 | ILA116.08 Million ≈ $311.21K |
-6.95% |
| 2013-12-31 | ILA124.75 Million ≈ $334.44K |
+158.49% |
| 2012-12-31 | ILA48.26 Million ≈ $129.38K |
+0.35% |
| 2011-12-31 | ILA48.09 Million ≈ $128.92K |
+187.42% |
| 2010-12-31 | ILA16.73 Million ≈ $44.86K |
-13.49% |
| 2009-12-31 | ILA19.34 Million ≈ $51.85K |
+101.24% |
| 2008-12-31 | ILA9.61 Million ≈ $25.76K |
+68.36% |
| 2007-12-31 | ILA5.71 Million ≈ $15.30K |
-65.11% |
| 2006-12-31 | ILA16.36 Million ≈ $43.87K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Evogene's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27407100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA363.00K | % |
| Other Components | ILA272.26 Million | % |
| Total Equity | ILA-1.45 Million | 100.00% |
Evogene Competitors by Market Cap
The table below lists competitors of Evogene ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mask Investments Limited
NSE:MASKINVEST
|
$5.21 Million |
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
$5.22 Million |
|
Prophecy International Holdings Ltd
AU:PRO
|
$5.22 Million |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
$5.23 Million |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
$5.21 Million |
|
Modus Therapeutics Holding AB
ST:MODTX
|
$5.21 Million |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
$5.21 Million |
|
Snail, Inc. Class A Common Stock
NASDAQ:SNAL
|
$5.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evogene's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,053,000 to -1,451,000, a change of -13,504,000 (-112.0%).
- Net loss of 16,485,000 reduced equity.
- New share issuances of 123,000 increased equity.
- Other factors increased equity by 2,858,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-16.48 Million | -1136.11% |
| Share Issuances | ILA123.00K | +8.48% |
| Other Changes | ILA2.86 Million | +196.97% |
| Total Change | ILA- | -112.04% |
Book Value vs Market Value Analysis
This analysis compares Evogene's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | ILA2.57 | ILA223.00 | x |
| 2012-12-31 | ILA2.62 | ILA223.00 | x |
| 2013-12-31 | ILA6.32 | ILA223.00 | x |
| 2014-12-31 | ILA4.63 | ILA223.00 | x |
| 2015-12-31 | ILA4.10 | ILA223.00 | x |
| 2016-12-31 | ILA3.43 | ILA223.00 | x |
| 2017-12-31 | ILA2.70 | ILA223.00 | x |
| 2018-12-31 | ILA1.94 | ILA223.00 | x |
| 2019-12-31 | ILA1.95 | ILA223.00 | x |
| 2020-12-31 | ILA1.64 | ILA223.00 | x |
| 2021-12-31 | ILA1.34 | ILA223.00 | x |
| 2022-12-31 | ILA0.68 | ILA223.00 | x |
| 2023-12-31 | ILA0.26 | ILA223.00 | x |
| 2024-12-31 | ILA-0.25 | ILA223.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evogene utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -193.69%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-42.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1.34% | 4.33% | 0.22x | 1.41x | ILA-4.16 Million |
| 2012 | -5.23% | -14.77% | 0.26x | 1.34x | ILA-7.35 Million |
| 2013 | -7.12% | -50.50% | 0.13x | 1.10x | ILA-21.35 Million |
| 2014 | -12.52% | -100.13% | 0.11x | 1.10x | ILA-26.14 Million |
| 2015 | -16.59% | -154.67% | 0.10x | 1.09x | ILA-27.59 Million |
| 2016 | -22.44% | -299.57% | 0.07x | 1.10x | ILA-28.32 Million |
| 2017 | -30.04% | -616.33% | 0.04x | 1.12x | ILA-27.78 Million |
| 2018 | -41.47% | -1188.21% | 0.03x | 1.17x | ILA-25.76 Million |
| 2019 | -38.12% | -2538.51% | 0.01x | 1.42x | ILA-24.13 Million |
| 2020 | -56.91% | -2519.81% | 0.01x | 1.56x | ILA-30.81 Million |
| 2021 | -56.35% | -3273.66% | 0.01x | 1.41x | ILA-35.85 Million |
| 2022 | -106.85% | -1781.73% | 0.03x | 2.01x | ILA-32.64 Million |
| 2023 | -198.12% | -423.39% | 0.11x | 4.24x | ILA-25.08 Million |
| 2024 | 0.00% | -193.69% | 0.21x | 0.00x | ILA-16.34 Million |
Industry Comparison
This section compares Evogene's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $62,485,111
- Average return on equity (ROE) among peers: -48.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evogene (EVGN) | ILA17.25 Million | 1.34% | 0.51x | $5.21 Million |
| BioLine RX Ltd (BLRX) | $117.94 Million | 0.00% | 0.35x | $11.20 Million |
| BioLight Life Sciences Ltd (BOLT) | $68.15 Million | -18.48% | 0.10x | $6.55 Million |
| Bonus Biogroup (BONS) | $-9.38 Million | 0.00% | 0.00x | $131.20 Million |
| Can Fite Biopharma Ltd (CANF) | $6.07 Million | -237.78% | 0.57x | $5.45 Million |
| Clal Biotechnology Industries Ltd (CBI) | $338.37 Million | -26.47% | 0.31x | $14.34 Million |
| Compugen (CGEN) | $12.79 Million | -63.57% | 0.21x | $205.33 Million |
| DNA Biomed Solns (DNA) | $11.53 Million | 0.00% | 0.84x | $37.64 Million |
| Enlivex Therapeutics Ltd (ENLV) | $17.93 Million | -85.68% | 0.14x | $519.31K |
| Kadimastem Ltd (KDST) | $-1.02 Million | 0.00% | 0.00x | $22.18 Million |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more